5.11

4.72% 0.24

Y Mabs Therapeutics Inc (YMAB)

Panoramica Notizia Cronologia dei prezzi Catena di opzioni Financials Forum Previsione

Precedente Chiudi:

$4.87

Aprire:

$4.8

Volume 24 ore:

66,053

Relative Volume:

0.25

Capitalizzazione di mercato:

$230.48M

Reddito:

$84.82M

Utile/perdita netta:

$-21.43M

Rapporto P/E:

-10.43

EPS:

-0.49

Flusso di cassa netto:

$-27.23M

1 W Prestazione:

+10.39%

1M Prestazione:

+15.65%

6M Prestazione:

-50.87%

1 anno Prestazione:

-57.57%

Intervallo 1D:

$4.80

$5.13

Intervallo di 1 settimana:

$4.485

$5.13

Portata 52W:

$3.55

$16.11

Y Mabs Therapeutics Inc Stock (YMAB) Company Profile

Nome

Y Mabs Therapeutics Inc

Settore

Healthcare (1169)

Industria

Biotechnology (665)

Telefono

646-885-8505

Indirizzo

202 CARNEGIE CENTER, PRINCETON, NY

Dipendente

107

Cinguettio

Prossima data di guadagno

2025-03-04

Ultimi documenti SEC

YMAB's Discussions on Twitter

Confronta YMAB con altri titoli

Azioni	Prezzo	Cap. di mercato	Reddito	Reddito netto	Flusso di cassa	EPS
YMAB Y Mabs Therapeutics Inc	5.09	199.75M	84.82M	-21.43M	-27.23M	-0.49
ONC Beone Medicines Ltd Adr	260.19	26.01B	3.81B	-644.79M	-669.77M	-6.24
VRTX Vertex Pharmaceuticals Inc	450.23	114.53B	11.10B	-988.90M	-1.26B	-3.92
AKTX Akari Therapeutics Plc Adr	1.365	40.54M	0	0	0	0.00
VRNA Verona Pharma Plc Adr	85.88	6.29B	0	-153.72M	-103.81M	-2.00
REGN Regeneron Pharmaceuticals Inc	497.75	65.13B	14.09B	4.50B	2.96B	39.28

Y Mabs Therapeutics Inc Stock (YMAB) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2025-04-22	Downgrade	BofA Securities	Neutral → Underperform
2024-11-18	Iniziato	Oppenheimer	Outperform
2024-08-16	Iniziato	Cantor Fitzgerald	Overweight
2024-06-28	Iniziato	Truist	Buy
2023-05-10	Aggiornamento	Wedbush	Neutral → Outperform
2023-04-03	Downgrade	Guggenheim	Buy → Neutral
2023-01-27	Downgrade	Morgan Stanley	Equal-Weight → Underweight
2023-01-05	Downgrade	Cowen	Outperform → Market Perform
2022-12-02	Downgrade	BofA Securities	Buy → Neutral
2022-10-31	Downgrade	JP Morgan	Neutral → Underweight
2022-10-31	Downgrade	Wedbush	Outperform → Neutral
2022-07-06	Ripresa	Canaccord Genuity	Buy
2022-06-24	Iniziato	BMO Capital Markets	Outperform
2022-02-03	Ripresa	Guggenheim	Buy
2021-11-19	Ripresa	Morgan Stanley	Equal-Weight
2021-11-16	Downgrade	JP Morgan	Overweight → Neutral
2021-05-07	Aggiornamento	BofA Securities	Neutral → Buy
2021-04-23	Ripresa	Cowen	Outperform
2021-03-22	Ripresa	JP Morgan	Overweight
2021-01-15	Downgrade	BofA Securities	Buy → Neutral
2020-11-09	Reiterato	H.C. Wainwright	Buy
2020-05-05	Iniziato	Barclays	Overweight
2020-05-01	Iniziato	Janney	Buy
2020-04-29	Iniziato	Morgan Stanley	Equal-Weight
2019-12-24	Iniziato	JP Morgan	Overweight
2019-11-20	Iniziato	Guggenheim	Buy
2019-09-04	Iniziato	Wedbush	Outperform
2019-04-01	Iniziato	H.C. Wainwright	Buy
2018-10-16	Iniziato	BTIG Research	Buy
2018-10-16	Iniziato	BofA/Merrill	Buy

Mostra tutto

Y Mabs Therapeutics Inc Borsa (YMAB) Ultime notizie

Jun 03, 2025

YMAB CLASS ACTION: Hagens Berman, National Trial Attorneys, Encourages Y-mAbs Therapeutics (YMAB) Investors with Significant Losses to Contact the Firm’s Attorneys, Securities Class Action Pending - ACCESS Newswire

Jun 03, 2025

Jun 02, 2025

MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. Has $179,000 Position in Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) - Defense World

Jun 02, 2025

Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Shares Acquired by Deutsche Bank AG - Defense World

Jun 02, 2025

May 30, 2025

Y-mAbs Therapeutics (NASDAQ:YMAB) Price Target Lowered to $15.00 at Oppenheimer - Defense World

May 30, 2025

May 29, 2025

Clear Street Reaffirms Their Buy Rating on Y-Mabs Therapeutics (YMAB) - The Globe and Mail

May 29, 2025

How the (YMAB) price action is used to our Advantage - news.stocktradersdaily.com

May 29, 2025

Oppenheimer Adjusts Target Price for Y-mAbs Therapeutics (YMAB) - GuruFocus

May 29, 2025

Y-mAbs Therapeutics (YMAB) Target Price Lowered by Oppenheimer | YMAB Stock News - GuruFocus

May 29, 2025

Oppenheimer Adjusts Price Target on Y-mAbs Therapeutics to $15 From $20, Maintains Outperform Rating - marketscreener.com

May 29, 2025

Cautious Outlook on Y-Mabs Therapeutics Due to Delayed Milestones and Early-Stage Pipeline - TipRanks

May 29, 2025

Y-mAbs Therapeutics’ (YMAB) “Outperform” Rating Reaffirmed at Wedbush - Defense World

May 29, 2025

May 28, 2025

Transcript : Y-mAbs Therapeutics, Inc.Special Call - marketscreener.com

May 28, 2025

Wedbush Lowers Price Target on Y-mAbs Therapeutics to $18 From $21, Maintains Outperform Rating - marketscreener.com

May 28, 2025

Y-Mabs Therapeutics Updates on Radiopharmaceutical Progress - TipRanks

May 28, 2025

Y-mAbs Therapeutics Announces Positive Phase 1 Trial Results for GD2-SADA in Metastatic Solid Tumors and Expands Radiopharmaceutical Pipeline - Nasdaq

May 28, 2025

Clinical Trial Success: Y-mAbs Breakthrough in Cancer Treatment Shows Promise with Novel Radiopharmaceutical - Stock Titan

May 28, 2025

May 27, 2025